Pfizer Still Examining Breakup While Analysts See Lower Odds

  • CEO Read said that there is no ‘wrong answer’ in decision
  • ‘It really doesn’t sound like they’re going to,’ analyst says

Five months out from Pfizer Inc.’s self-imposed deadline on whether to break into two separate companies, Chief Executive Officer Ian Read made clear he’s still mulling whether the drug giant is better together or apart.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.